{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yau K"],"funding":["COVID-19 Immunity Task Force"],"pagination":["20543581231160511"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10028441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Background</h4>People living with chronic kidney disease (CKD) have been disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic, including higher rates of infection, hospitalization, and death. Data on responsiveness to COVID-19 vaccination strategies and immunogenicity are limited, yet required to inform vaccination strategies in this at-risk population.<h4>Objective</h4>The objective of this study is to characterize the longitudinal serologic response to COVID-19 vaccination.<h4>Design</h4>This is a prospective observational cohort study.<h4>Setting</h4>Participating outpatient kidney programs within Ontario and British Columbia.<h4>Patients</h4>Up to 2500 participants with CKD G3b-5D receiving COVID-19 vaccination, including participants receiving dialysis a"],"journal":["Canadian journal of kidney health and disease"],"pubmed_title":["Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol."],"pmcid":["PMC10028441"],"funding_grant_id":["No. 2122-HQ-000071"],"pubmed_authors":["Siwakoti A","Hladunewich MA","Tran V","Dhruve M","Enilama O","Kozak R","Romney MG","Leis JA","Chan CT","Levin A","Colwill K","Yau K","Kandel C","Oliver MJ","Blake P","Perl J","Singer J","Tsui H","Bolotin S","Abe KT","Estrada-Codecido J","Hu Q","Tam P","Brown T","Gingras AC"],"additional_accession":[]},"is_claimable":false,"name":"Determining the Longitudinal Serologic Response to COVID-19 Vaccination in the Chronic Kidney Disease Population: A Clinical Research Protocol.","description":"<h4>Background</h4>People living with chronic kidney disease (CKD) have been disproportionately affected by the coronavirus disease 2019 (COVID-19) pandemic, including higher rates of infection, hospitalization, and death. Data on responsiveness to COVID-19 vaccination strategies and immunogenicity are limited, yet required to inform vaccination strategies in this at-risk population.<h4>Objective</h4>The objective of this study is to characterize the longitudinal serologic response to COVID-19 vaccination.<h4>Design</h4>This is a prospective observational cohort study.<h4>Setting</h4>Participating outpatient kidney programs within Ontario and British Columbia.<h4>Patients</h4>Up to 2500 participants with CKD G3b-5D receiving COVID-19 vaccination, including participants receiving dialysis a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-05-28T10:58:48.712Z","creation":"2024-11-05T18:06:54.621Z"},"accession":"S-EPMC10028441","cross_references":{"pubmed":["36950028"],"doi":["10.1177/20543581231160511"]}}